DSIP (Delta Sleep-Inducing Peptide): Reference Overview and Reconstitution Notes

DSIP (Delta Sleep-Inducing Peptide)

What it is

DSIP, short for Delta Sleep-Inducing Peptide, is a small, naturally occurring neuropeptide, specifically a nonapeptide of nine amino acids (sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) with a molecular weight near 850 daltons and an amphipathic structure, meaning it carries both water-attracting and water-repelling regions. It was first isolated in the 1970s from the cerebral venous blood of rabbits during induced sleep, and its name comes from early reports that it increased delta-wave (slow-wave) EEG activity. Material sold for laboratory use is produced by peptide synthesis rather than extracted from tissue.

Research context and categorization

DSIP is generally grouped under the sleep-regulating and neuroendocrine category of research peptides. In the published literature it is most commonly discussed in relation to sleep architecture and slow-wave sleep, and it has also been investigated in the context of stress adaptation and regulation of the hypothalamic-pituitary-adrenal (HPA) axis, pain and opioid-receptor modulation, neuroprotection, and various hormone-secretion pathways. Because of these threads it is sometimes discussed alongside recovery and stress-response research rather than as a sleep agent alone.

It is important to note that much of this work is old, small in scale, and inconsistent, and that findings have been described as controversial within the literature. Human evidence is limited. These uses are investigational, and the reported effects are not confirmed or approved outcomes in people. Nothing here should be read as an established benefit.

Status

  • Regulatory status: Research-only. DSIP is not approved by the FDA for insomnia, anxiety, depression, or any other medical condition. It remains an investigational, unapproved substance. A regulatory review of DSIP (under the name emideltide) for the Section 503A compounding list has been discussed for a 2026 advisory committee meeting, but that process does not by itself constitute approval.
  • Sport status: Not specifically named on the WADA Prohibited List. However, because DSIP is not an approved therapeutic substance, it can fall under class S0, Non-Approved Substances, which prohibits at all times any substance that has no current approval by a governmental regulatory health authority for human therapeutic use. Athletes subject to testing should treat it as potentially prohibited and verify current status directly with their sport's anti-doping authority before use.

Reconstitution notes (general)

Lyophilized (freeze-dried) peptides are typically reconstituted with bacteriostatic water before measurement. The working concentration is simple to calculate: concentration equals the milligrams of peptide in the vial divided by the millilitres of bacteriostatic water added. For example, 5 mg of powder in 2.5 mL of water gives 2 mg/mL. A reconstitution calculator is available at /pages/tools to check the math for a given vial and fill volume.

Dilution and handling notes (compound-specific)

DSIP is supplied as a lyophilized powder, commonly in 5 mg or 10 mg vials, and is reconstituted for laboratory use. Reported working concentrations commonly fall in the range of roughly 1 to 5 mg/mL, so a 5 mg vial is often paired with about 1 to 2 mL of bacteriostatic water and a 10 mg vial with about 2 to 3 mL. The volume chosen is a matter of the concentration the researcher wants for accurate small-volume measurement, not a fixed rule. More water gives a more dilute solution that is easier to measure in fine increments; less water gives a more concentrated solution in less liquid. DSIP dissolves readily and normally reaches its final appearance within a few minutes of gentle mixing, without gelling.

Because DSIP is amphipathic, a faint haze or opalescence can be seen and is common at higher concentrations, roughly above 1 mg/mL, and is not by itself a sign of a bad mix. Very dilute solutions, below roughly 0.5 mg/mL, tend to look crystal-clear, while pushing concentration much higher, above about 10 mg/mL, raises the risk of visible crystalline precipitate. The practical fix is to keep the concentration in the moderate range rather than over-concentrating a single vial. A cloudiness that appears and then will not clear, or that persists well past the first several minutes, points to aggregation rather than normal opalescence and is treated as a problem.

Two further handling quirks are worth noting. First, DSIP contains a tryptophan residue and is light-sensitive, so it is kept out of direct light, using amber vials or shielded storage, to limit oxidation. Second, add the bacteriostatic water slowly down the inner glass wall of the vial rather than jetting it directly onto the powder cake, and swirl or roll the vial gently rather than shaking or vortexing, since vigorous agitation foams the liquid and the air-liquid interface can degrade peptide molecules. Letting both vials reach room temperature and wiping the stoppers with an alcohol swab before mixing helps the powder dissolve cleanly. After mixing, the solution is inspected for clarity before use.

Handling and storage

Store the reconstituted vial refrigerated at 2 to 8 degrees Celsius and keep it out of light. Wipe the rubber stopper with an alcohol swab before each puncture. Label the vial with the mix date so its age can be tracked. A refrigerated working window of roughly four weeks (about 28 days) is commonly cited for solutions made with bacteriostatic water. Discard any vial that becomes cloudy in a way that does not clear, is discolored, or shows floaters or particulates.

Related reading

Tools and supplies

For laboratory and research reference only. Educational content, not medical, dosing, injection, or therapeutic guidance, and not intended for human or animal use. Any research uses described are investigational and not confirmed or approved benefits. Confirm anything involving health with a licensed professional. References linked above.